Novel strategies for overcoming multidrug resistance in cancer

BioDrugs

Volumn 16, Issue 2, 2002, Pages 97-103

  Baguley, Bruce C ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; GLYCOPROTEIN P; N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE; PROTEIN INHIBITOR; VALSPODAR; XR 5000;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL KINETICS; CELL LOSS; CELL POPULATION; DRUG TARGETING; DRUG TRANSPORT; MEMBRANE PERMEABILITY; MOLECULAR WEIGHT; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN SECRETION; REVIEW; TUMOR CELL;

EID: 0036093852     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200216020-00003     Document Type: Review

References (68)

1. The genetic origin of drug resistance in neoplasms: Implications for systemic therapy
2. Cross resistance between Vinca alkaloids and anthracyclines in Ehrlich ascites tumor in vivo
3. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines
4. ABC transporters: From microorganisms to man
5. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
6. A multidrug resistance transporter from human MCF-7 breast cancer cells
7. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump
8. From MDR to MXR: New understanding of multidrug resistance systems, their properties and clinical significance
9. Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein
10. Evidence that vault ribonucleoprotein particles localize to the nuclear pore complex
11. Up-regulation of vaults may be necessary but not sufficient for multidrug resistance
12. Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26)
13. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil
14. Potentiation of the reversal activity of SDZ PSC833 on multi-drug resistance by an anti-P-glycoprotein monoclonal antibody MRK-16
15. Structure of msbA from E. coli: A homolog of the multidrug resistance ATP binding cassette (ABC) transporters
16. Reversal of acquired resistance to Vinca alkaloids and anthracycline antibiotics
17. Multidrug resistance in oncology: Diagnostic and therapeutic approaches
18. Can multidrug resistance mechanisms be modified?
19. Reversal of LRP-associated drug resistance in colon carcinoma SW-620 cells
20. Design of DNA intercalators to overcome topoisomerase II-mediated multidrug resistance
21. The potential of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide to circumvent three multidrug-resistance phenotypes in vitro
22. Mechanism of resistance of non-cycling mammalian cells to 4′-(9-acridinylamino)-methanesulfon-m-anisidide (m-AMSA): Comparison of uptake, metabolism and DNA breakage in log- and plateau-phase Chinese hamster fibroblast cell cultures
23. Cellular uptake of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and related compounds: The relationship between lipophilicity and susceptibility to multidrug resistance
24. Kinetics of anthracycline accumulation in multidrug-resistant tumor cells: Relationship to drug lipophilicity and serum albumin binding
25. Analysis of drug transport kinetics in multidrug-resistant cells: Implications for drug action
26. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer
27. Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs
28. Functional involvement of P-glycoprotein in blood-brain barrier
29. Signal transduction pathways and transcriptional mechanisms as targets for prevention of emergence of multidrug resistance in human cancer cells
30. A carbamate analogue of amsacrine with activity against non-cycling cells stimulates topoisomerase II cleavage at DNA sites distinct from those of amsacrine
31. Carbamate analogues of amsacrine active against non-cycling cells: Relative activity against topoisomerases IIα and IIβ
32. From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine 4-carboxamide): Selectivity for topoisomerases I and II among acridine derivatives
33. Activation of programmed cell death by anticancer agents: Cisplatin as a model system
34. Apoptosis induced by anticancer drugs
35. Apoptosis: A basic biological phenomenon with wide ranging implications in tissue kinetics
36. Role of p53 and p21(waf1/cip1) in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs
37. Mitochondrial control of cell death
38. Structural and biochemical basis of apoptotic activation by Smac/DIABLO
39. Bcl-2 family members and the mitochondria in apoptosis
40. Bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis
41. Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells
42. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells
43. Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-α (ISIS 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: Relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells
44. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence
45. Targeting tumor cell resistance to apoptosis induction with antisense oligonucleotides: Progress and therapeutic potential
46. Genasense (Genta Inc)
47. TNF- and cancer therapy-induced apoptosis-potentiation by inhibition of NF-κ-B
48. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of Ikappa B kinase
49. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor
50. Activation of p53 in cervical carcinoma cells by small molecules
51. Apoptosis-regulating proteins as targets for drug discovery
52. Ceramide enables Fas to cap and kill
53. Targeting ceramide metabolism - A strategy for overcoming drug resistance
54. Ceramide glycosylation potentiates cellular multidrug resistance
55. The phosphatidylinositide 3′-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C
56. Repopulation kinetics during fractionated irradiation and the relationship to the potential doubling time, Tpot
57. Evidence of cell kinetics as predictive factor of response to radiotherapy alone or chemoradiotherapy in patients with advanced head and neck cancer
58. Experimental evaluation of potential anticancer agents XV. On the relative rates of growth and host kill of 'single' leukemia cells that survive in vivo cytoxan therapy
59. Contributions of cell kill and posttreatment tumor growth rates to the repopulation of intracerebral 9L tumors after chemotherapy: An MRI study
60. Short-term cultures of clinical tumor material: Potential contributions to oncology research
61. Cell production rates in human tissues and tumours and their significance. Part II: Clinical data
62. Measurement of cell kinetics in human tumours in vivo using bromodeoxyuridine incorporation and flow cytometry
63. Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer
64. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (cdk)2 and cdk4 in human breast carcinoma cells
65. Pleiotropic resistance to DNA-interactive drugs is associated with increased expression of genes involved in DNA replication, repair, and stress response
66. Chemosensitivity prediction by transcriptional profiling
67. Proteomics for studying cancer cells and the development of chemoresistance
68. What does positron emission tomography offer oncology?